Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-64673

Tabatabai, G; Hegi, M; Stupp, R; Weller, M (2012). Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Current Neurology and Neuroscience Reports, 12(3):302-307.

[img]Published Version
PDF - Registered users only
163kB

Abstract

Malignant gliomas are currently diagnosed based on morphological criteria and graded according to the World Health Organization classification of primary brain tumors. This algorithm of diagnosis and classification provides clinicians with an estimated prognosis of the natural course of the disease. It does not reflect the expected response to specific treatments beyond surgery (eg, radiotherapy or alkylating chemotherapy). Clinical experience has revealed that gliomas sharing similar histomorphological criteria might indeed have different clinical courses and exhibit highly heterogenous responses to treatments. This was very impressively demonstrated first for oligodendrogliomas. The presence or lack of combined deletions of the chromosomal segments 1p/19q was associated with different benefit from radiotherapy and chemotherapy. We review current molecular markers for malignant gliomas and discuss their current and future impact on clinical neuro-oncology.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
DDC:610 Medicine & health
Language:English
Date:2012
Deposited On:18 Sep 2012 09:46
Last Modified:06 Dec 2013 15:03
Publisher:Current Science
ISSN:1528-4042
Publisher DOI:10.1007/s11910-012-0263-x
PubMed ID:22427102
Citations:Web of Science®. Times Cited: 11
Google Scholar™
Scopus®. Citation Count: 13

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page